Last reviewed · How we verify

DeNova Research — Portfolio Competitive Intelligence Brief

DeNova Research pipeline: 1 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Calcium hydroxylapatite Calcium hydroxylapatite marketed
Volbella or Juvederm Ultra XC filler Volbella or Juvederm Ultra XC filler phase 3 Hyaluronic acid filler Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Chang Gung Memorial Hospital · 1 shared drug class
  2. Ethicon, Inc. · 1 shared drug class
  3. Mallinckrodt · 1 shared drug class
  4. Sun Yat-sen University · 1 shared drug class
  5. Swiss Cancer Institute · 1 shared drug class
  6. Takeda · 1 shared drug class
  7. WakeMed Health and Hospitals · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for DeNova Research:

Cite this brief

Drug Landscape (2026). DeNova Research — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/denova-research. Accessed 2026-05-14.

Related